{"DataElement":{"publicId":"3787617","version":"1","preferredName":"Patient Plan Control Group Treatment Regimen Type","preferredDefinition":"the type of treatment plan that specifies the dosage, the schedule, and the duration of treatment planned for the control group and used as a standard for a person who receives medical attention, care, or treatment.","longName":"Pati_Plan_Cont_Trea_Cont_Prot_","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3787613","version":"1","preferredName":"Patient Plan Control Group Treatment Regimen","preferredDefinition":"information related to a treatment plan that specifies the dosage, the schedule, and the duration of treatment planned for a control group (the group used as a standard of comparison in a controlled experiment) for a person who receives medical attention, care, or treatment.","longName":"Pati_Plan_Cont_Trea","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3787611","version":"1","preferredName":"Plan Control Group Treatment Regimen","preferredDefinition":"Planned; devised, contrived, or formed in design.:A group used as a standard of comparison in a control experiment.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C25619:C28143:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Control Group","conceptCode":"C28143","definition":"A group used as a standard of comparison in a control experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6019E4-10AB-F5E8-E040-BB89AD437848","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6019E4-10BC-F5E8-E040-BB89AD437848","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3787616","version":"1","preferredName":"Control Group Protocol Treatment Arm Type","preferredDefinition":"Something distinguishable for a specific treatment plan within a clinical trial used as a standard of comparison in a controlled experiment.","longName":"Cont_Prot_Type","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Topotecan Regimen","valueDescription":"Topotecan","ValueMeaning":{"publicId":"3380233","version":"1","preferredName":"Topotecan","longName":"3380233","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1648-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6019E4-10FF-F5E8-E040-BB89AD437848","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","deletedIndicator":"No"},{"value":"Pegylated Liposomal Doxorubicin Regimen","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"2576633","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"2576633","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F866-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6019E4-1113-F5E8-E040-BB89AD437848","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","deletedIndicator":"No"},{"value":"Paclitaxel Regimen","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6019E4-1127-F5E8-E040-BB89AD437848","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","deletedIndicator":"No"},{"value":"Tamoxifen Regimen","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6019E4-113B-F5E8-E040-BB89AD437848","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","deletedIndicator":"No"},{"value":"Letrozole Regimen","valueDescription":"Letrozole","ValueMeaning":{"publicId":"2921027","version":"1","preferredName":"Letrozole","longName":"2921027","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD52-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF6019E4-114F-F5E8-E040-BB89AD437848","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"ONEDATA","dateModified":"2013-06-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6019E4-10E2-F5E8-E040-BB89AD437848","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"SBR","dateModified":"2013-08-01","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"}]}],"AlternateNames":[{"name":"Pati_Plan_Cont_Trea_Cont_Prot_","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If the patient is randomized","type":"Preferred Question Text","description":"If the patient is randomized to the control arm, what is the planned treatment regimen?","url":null,"context":"CTEP"},{"name":"NRG_CRF text","type":"Alternate Question Text","description":"If the patient is randomized to arm 1 (the non-platinum based chemotherapy arm), please select the regimen the patient will be receiving:","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF6019E4-1159-F5E8-E040-BB89AD437848","latestVersionIndicator":"Yes","beginDate":"2013-06-17","endDate":null,"createdBy":"REBOYJ","dateCreated":"2013-06-17","modifiedBy":"GEDEONL","dateModified":"2016-01-19","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}